慢性肺曲霉病初始维持治疗口服抗真菌药选择:纵向分析
该回顾性随访观察研究纳入两项既往多中心试验中的273例慢性肺曲霉病患者,比较急性静脉治疗结束后初始维持治疗使用口服伊曲康唑(ITCZ)与口服伏立康唑(VRCZ)的疗效。初始维持治疗选择对总死亡率及CPA相关死亡率无显著影响,但ITCZ选择与再入院及换药风险独立相关。
要点
- VRCZ初始维持治疗的临床改善率高于ITCZ(40.0% vs 18.2%)。
- ITCZ选择为再入院(OR 3.1)及换药(OR 5.7)的独立危险因素。
核心结论
- 口服VRCZ用于初始维持治疗在CPA患者临床改善方面优于口服ITCZ。
- VRCZ与ITCZ初始维持治疗在粗死亡率上无差异,尤其在老年CPA患者中。
研究设计与样本
- 回顾性、随访、观察性研究,纳入两项既往多中心试验中登记的CPA患者。
- 共273例CPA患者,其中59例和101例分别在急性静脉治疗结束后开始口服ITCZ和口服VRCZ维持治疗。
- 本随访研究观察期中位数为731天。
主要发现
- 观察期末ITCZ组临床改善比例为18.2%,VRCZ组为40.0%。
- 多变量Cox回归显示初始维持治疗选择(ITCZ或VRCZ)对总死亡率及CPA相关死亡率无显著影响。
- 多变量logistic回归显示口服ITCZ作为初始维持治疗是再入院的独立危险因素(OR 3.1;95%CI 1.3-7.5)。
- 口服ITCZ作为初始维持治疗是换用其他抗真菌药的独立危险因素(OR 5.7;95%CI 2.0-15.7)。
临床怎么用
- CPA急性静脉治疗结束后选择初始维持治疗时,可优先考虑口服VRCZ以争取更高临床改善率并降低再入院和换药风险。
- 对老年CPA患者,VRCZ与ITCZ在粗死亡率上无差异,选药需综合疗效与安全性。
局限性
- 为回顾性观察性研究,非随机对照直接比较。
- 初始维持治疗分组并非随机分配,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data for direct comparisons of the efficacy of oral itraconazole (ITCZ) and oral voriconazole (VRCZ) therapy in the treatment of chronic pulmonary aspergillosis (CPA). METHODS: We conducted a retrospective, follow-up, observational study of CPA patients enrolled in 2 previous multicenter trials. RESULTS: Of the 273 CPA patients, 59 and 101 patients started maintenance therapy with oral ITCZ and oral VRCZ, respectively, just after the end of acute intravenous therapy in each trial. At the end of the observation period in this follow-up study (median observation period, 731 days), the percentage of patients who showed improvement was lower in the ITCZ group than in the VRCZ group (18.2% vs 40.0%). However, after including stable patients, the percentages were 50.9% and 52.6%, respectively, in the ITCZ and VRCZ groups, which were not significantly different (P = .652). Multivariable Cox regression analysis showed no significant influence of the choice of initial maintenance treatment (ITCZ or VRCZ) on overall mortality as well as CPA-associated mortality. Multivariable logistic regression showed that oral ITCZ selection for initial maintenance therapy was an independent risk factor for hospital readmission and switching to other antifungal agents (odds ratio [OR], 3.1; 95% confidence interval [CI], 1.3-7.5 and OR, 5.7; 95% CI, 2.0-15.7, respectively). CONCLUSIONS: Oral VRCZ for initial maintenance therapy showed better effectiveness than oral ITCZ for clinical improvement in CPA patients. There was no difference in crude mortality between initial maintenance therapy with VRCZ and ITCZ, especially in elderly CPA patients. CLINICAL TRIALS REGISTRATION: UMIN000007055.
引用
- Tashiro M, Takazono T, Saijo T, et al. Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis. Clin Infect Dis. 2020. PMID: 30959519. doi:10.1093/cid/ciz287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。